ISSN: 2376-127X

妊娠と小児の健康に関するジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

インデックス付き
  • 索引コペルニクス
  • Google スカラー
  • アカデミックキー
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • パブロン
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • ICMJE
このページをシェアする

抽象的な

The Effect of a Novel Multi-Ingredient Supplement in Pregnant Women

Marco Rigatti, Agostino Menditto, Renato De Stefano, Civetta Antonio, Umberto Landri, Roberto Passaro, Mario Passaro, Fabrizio Paolillo Diodati, Alessandro Nicotra, Emio Cafarelli, Ermanno Barletta, Antonio Esposito, Pierluigi Pozzuoli

Objective: to investigate the effects of a novel multi-ingredient supplement comprised of high dose whey protein, to improve maternal and perinatal outcomes in pregnant women

Methods: This was an observational retrospective study. Women who received oral supplementation with a novel multi-ingredient supplement (PSIPROTO ®), comprised of high dose whey protein, were compared with women who did not. Inclusion criteria were singleton pregnancy with body mass index (BMI) higher than 25. The primary outcome of the study was the incidence of adverse pregnancy outcome

Results: 400 women, 200 for each group, were included in the study. The two groups were similar in terms of maternal demographics, and both of them had similar BMI. Maternal age and smoking rate were also similar. Women who received the intervention had a significantly lower maternal weight gain, and lower risk of low birth weight. Notably, 4 women in the intervention group reported intrauterine growth restriction before the intervention, and solved after 2 months of supplementation.

Conclusion: Our retrospective cohort of singleton gestations with BMI >25 showed that PSIPROTO is a safe and efficacy supplement in pregnancy.